- Home
- CGBD vs KURA Comparison
CGBD vs KURA Comparison
Compare CGBD & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGBD | KURA |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | 2500 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 742.2M | 841.6M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CGBD | KURA |
|---|---|---|
| Price | $10.85 | $10.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 11 |
| Target Price | $12.92 | ★ $25.56 |
| AVG Volume (30 Days) | 513.8K | ★ 1.8M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 14.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | $3.74 | $28.28 |
| Revenue Next Year | $1.80 | $106.37 |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $10.62 | $5.45 |
| 52 Week High | $14.32 | $12.49 |
Technical Indicators
Market Signals| Indicator | CGBD | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 56.79 |
| Support Level | $10.68 | $8.80 |
| Resistance Level | $12.17 | $11.17 |
| Average True Range (ATR) | 0.27 | 0.63 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 16.82 | 53.80 |
Price Performance
Historical ComparisonAbout CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.